FrançaisAre analysts right about Gilead Sciences (GILD)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Gilead Sciences, we replayed every analyst price target of the past 12 months and measured the real outcome: 49% were profitable, average return +23% (220 calls). At 3 months: +4% average return (44% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| Piper Sandler | 15 | 47% | +24% |
| BMO Capital | 14 | 57% | +29% |
| Oppenheimer | 14 | 50% | +12% |
| Morgan Stanley | 13 | 54% | +23% |
| Deutsche Bank | 13 | 85% | +51% |
💵 Dividend : Gilead Sciences pays about $3.22/share/yr → 2.56% yield. what is this?
Frequently asked questions
Is Gilead Sciences a buy right now?
The analyst consensus on Gilead Sciences (GILD) is "Buy" (36 bullish, 0 bearish calls over 12 months). This is not advice: historically, 49% of their targets on this stock turned out profitable over 1 year.
What is Gilead Sciences's price target?
The median 12-month price target is $156 (+5% vs $149), ranging from $123 to $180 (11 analysts).
Are analysts accurate on Gilead Sciences?
Over 1 year, 49% of analyst targets on Gilead Sciences were profitable, for an average return of +23% (across 220 timestamped calls). This is JPI Invest's accuracy metric.
What is the Gilead Sciences stock forecast?
Analysts target a median of $156 within 12 months, i.e. +5% vs the current price. The most bullish targets $180, the most cautious $123.
What is the Gilead Sciences stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $156, +5%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (49%), and the stock's past trajectory.
Is Gilead Sciences overvalued?
Detailed valuation data for Gilead Sciences is available in the interactive analysis.
📊 See the full interactive analysis of Gilead Sciences →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.